Immunocore Holdings plc
For the period ended Mar 31, 2026. Filed May 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 6, 2026
IMCR$32.38+2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows for the
Condensed Consolidated Statements of Cash Flows
(Unaudited) (In thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities | ||
| Net income | $12,971 | $5,023 |
| Adjustments for: | ||
| Share-based compensation expense | 6,302 | 9,489 |
| Depreciation | 948 | 854 |
| Unrealized foreign exchange gains, net | (3,490) | (2,907) |
| Unrealized gains on marketable securities | (1,776) | (5,469) |
| Non-cash lease expense | 627 | 546 |
| Other | 534 | 509 |
| Changes in assets and liabilities: | ||
| (Increase) decrease in accounts receivable | (7,930) | 836 |
| Increase in prepayments and other current assets | (18,772) | (28) |
| Increase in accounts payable | 5,974 | 3,342 |
| Decrease in accrued expenses | (8,303) | (10,943) |
| Decrease in deferred revenue | (146) | — |
| (Decrease) increase in operating lease liabilities | (864) | 756 |
| Decrease (increase) in other operating assets | 150 | (1,573) |
| Net cash (used in) provided by operating activities | (13,775) | 435 |
| Cash flows from investing activities | ||
| Proceeds from sale of marketable securities | 6,000 | 10,000 |
| Purchase of property and equipment | (1,781) | (298) |
| Net cash provided by investing activities | 4,219 | 9,702 |
| Cash flows from financing activities | ||
| Proceeds from exercise of share options | 656 | 2,551 |
| Net cash provided by financing activities | 656 | 2,551 |
| (Decrease) increase in cash and cash equivalents | (8,900) | 12,688 |
| Net foreign exchange difference on cash held | (6,134) | 8,426 |
| Cash and cash equivalents at beginning of period | 467,709 | 455,731 |
| Cash and cash equivalents at end of period | $452,675 | $476,845 |
| Supplemental disclosure of cash flow and noncash information | ||
| Cash paid for interest | $(5,031) | $(5,031) |
| Cash paid for income taxes, net of refunds | $(13) | $(32) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.